European Journal of Rheumatology

Journal Information
ISSN / EISSN : 2147-9720 / 2148-4279
Published by: AVES Publishing Co. (10.5152)
Total articles ≅ 519
Current Coverage
ESCI
PUBMED
PMC
DOAJ
Archived in
EBSCO
Filter:

Latest articles in this journal

Tanaka Ngcozana, Kevin Corbett, Ajay Bhatia
European Journal of Rheumatology, Volume 8, pp 202-206; https://doi.org/10.5152/eurjrheum.2021.20021

Abstract:
Rheumatoid arthritis (RA) is a chronic condition characterized by articular and non-articular features. Patients with RA have an increased risk of developing cardiovascular disease. This study aimed to ascertain what patients with RA know about their numbers (biomedical data, including blood pressure, cholesterol, disease activity score-28 joints [DAS28], and body mass index [BMI]) and to understand the barriers to patients knowing these health indicators and how their knowledge can be improved. A total of 50 consecutive patients from a clinic were approached to complete an anonymous survey in a nurse-led clinic. The questionnaire included 10 questions that assessed the demographic data, knowledge of biomedical data, importance of these data, and how their awareness could be increased. A total of 40 patients responded to the questionnaire; the estimated mean age was 58.1±13.4 (mean±standard deviation) years. Most respondents were females (87%). The highest disease category duration was 2-5 years (40% patients). Moreover, 30% of respondents were aware of the "know your numbers" concept; 90% did not know their BMI, and 75% did not know about their DAS28 score. Furthermore, 40% reported that they were not informed about their biomedical data; 95% of patients revealed that they would like to know their numbers; 27.5% suggested that a regularly updated and explained written record would be appropriate, and 35% proposed that a multidisciplinary input would be useful in regularly informing them of the numbers. This study has shown that although patients are not very familiar with all of their biomedical data, they are interested in knowing them. Knowing their biomedical data may encourage them to be more concerned about their health and even lead to improved RA self-management and health outcomes.
Helene Broch Tenstad, Pernille Just Vinholt, Christian Nielsen, Hanne Lindegaard, Søren Andreas Just
European Journal of Rheumatology, Volume 8, pp 8-4; https://doi.org/10.5152/eurjrheum.2021.20054

Abstract:
Fibrocytes are circulating bone-marrow-derived cells that migrate to organs with ongoing repair or inflammation. In the target organ, the cells differentiate, become long and spindle-shaped, and are able to produce extracellular matrix components. In fibrotic diseases, the levels of fibrocytes are increased, both in circulation and the diseased tissue. In rheumatoid arthritis (RA), fibrocytes have been proposed to be involved in the spread of the disease and possibly in RA fibrotic manifestations, as can be seen in RA interstitial lung disease (RA-ILD). Therefore, we aimed to investigate a range of current RA treatment modalities (corticosteroids and conventional and biological disease-modifying antirheumatic drugs (DMARDs)) regarding their effect on in vitro fibrocyte differentiation. A total of 10 participants were included (5 patients with RA and 5 healthy controls). Peripheral blood mononuclear cells (PBMCs) were isolated and cultured for 5 days with prednisolone, conventional DMARDs (methotrexate, sulfasalazine, and hydroxychloroquine), and biological DMARDs (etanercept, tocilizumab, adalimumab, abatacept, and rituximab). The numbers of fibrocytes were counted. Dose-response data for abatacept and tocilizumab were collected. Abatacept and prednisolone significantly suppressed differentiation of PBMC into fibrocytes compared with control (p=0.02 and p<0.01, respectively) (n=10). In overall analysis (n=10), abatacept reduced fibrocyte levels with an average of 44% overall and 71% in the RA group compared with the control wells. Tocilizumab reduced the fibrocyte count by 63% overall and 45% in the RA group, although it was not significant (p=0.07 and p=0.06, respectively). Both tocilizumab and abatacept display a dose-response relationship. Abatacept and prednisolone suppress the differentiation of mononuclear cells to mature fibrocytes in vitro in patients with RA, and data indicate a similar effect of tocilizumab; this was further supported by the observed dose-response relationship. Clinical trials are needed to compare the effect of these drugs on fibrotic RA manifestations, for example, RA-ILD.
Cemal Gürbüz, Demet Yalçın Kehribar, Metin Özgen
European Journal of Rheumatology, Volume 8, pp 211-216; https://doi.org/10.5152/eurjrheum.2020.21199

Panagiotis Panagopoulos, Naval Hospital Of Athens Clinic Of Rheumatology, Gkikas Katsifis
European Journal of Rheumatology, Volume 8, pp 228-231; https://doi.org/10.5152/eurjrheum.2021.20071

Seda Çolak, Tahsin Murat Turgay, Orhan Küçükşahin, Mustafa Türker Duman, Hülya Çetinkaya, Murat Toruner
European Journal of Rheumatology, Volume 8, pp 207-210; https://doi.org/10.5152/eurjrheum.2021.20090

Pratap Kumar Patra, Aaqib Zaffar Banday, Robin Bansal, Murugan Sudhakar, Ankur Kumar Jindal
European Journal of Rheumatology, Volume 8, pp 237-238; https://doi.org/10.5152/eurjrheum.2020.20068

Cosimo Bruni, Cosimo Cigolini, Giulia Tesei, Laura Cometi, Francesca Bartoli, Ginevra Fiori, Francesca Nacci, Silvia Bellando Randone, Serena Guiducci, Marco Matucci Cerinic
European Journal of Rheumatology, Volume 8, pp 190-195; https://doi.org/10.5152/eurjrheum.2020.21162

Fatma Alibaz-Öner, Haner Direskeneli
European Journal of Rheumatology, Volume 8, pp 217-222; https://doi.org/10.5152/eurjrheum.2020.20138

Abstract:
Behçet's disease (BD) significantly increases morbidity and mortality, especially in young men. While vascular involvement is the most frequent cause of mortality, ocular involvement, which can cause visual loss, is the most important cause of morbidity in BD. Immunosuppressive treatment is the mainstay for major organ involvement. However, despite optimal immunosuppressive treatment, relapses and disease-related damage develop in a subgroup of patients, especially among those with ocular or vascular involvement. With the recent understanding of the immuno-pathogenesis, biologic treatments targeting potential pathogenic cells, cytokines or pathways are better optimized in BD. Data from large series showed that tumor necrosis factor-α inhibitors and interferon-α are effective and safe treatment options for the treatment of refractory and major organ involvement, such as ocular, neurologic, vascular, and gastrointestinal. Anakinra and ustekinumab also seem to be promising agents for refractory mucocutaneous disease. IL-1 inhibitors and tocilizumab may be alternatives for the treatment of patients with refractory eye involvement. Still, randomized controlled trials of biologic agents, especially for the treatment of major organ involvement, are insufficient, and further prospective, long-term follow-up studies are needed to clarify the efficacy, safety, and optimal treatment duration of biologic agents in BD.
Back to Top Top